Bladder Cancer Detection Kit Market Research Report- Forecast till 2027

Bladder Cancer Detection Kit Market: by Sample Kit Technology [Fluorescence In Situ Hybridization (FISH), and Enzyme-Linked Immunosorbent Assay (ELISA)], End User (Hospitals & Clinics and Diagnostic Centers), Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast to 2027

ID: MRFR/HC/9185-HCR | September 2021 | Region: Global | 120 pages

Bladder Cancer Detection Kit Market Forecast


The bladder cancer detection kit market is expected to cross ~USD 322.4 million by 2027 at a CAGR of ~11.17%.


Bladder Cancer Detection Kit Market Overview:


Bladder cancer is a common type of cancer in which malignant cells develop in the tissues of the bladder. It often begins in the urothelial cells that line the inside of the bladder. These cells are found in the kidneys and the ureters. Hence, urothelial cancer can occur in the kidneys as well as in ureters.Various manufacturers provide bladder cancer detection kits across the worldwith several products in the R&D phase. For instance, Abbott Laboratories (US) UroVysion bladder cancer kit is marketed globally. This product is a multicolor FISH assay and multitarget that includes staining exfoliated cells in urine with four denatured, fluorescent, centromeric chromosome-enumeration probes.


According to Globocan, the global burden of bladder cancer is significantly high, representing 3.0% of all new cancer diagnoses, 2.1% of all cancer deaths in 2020, and the 11thmost frequently diagnosed cancer worldwide. Hence, the government authorities are keenly observing the development of the products related to bladder cancer detection kits. These authorities have offered guidelines for producing bladder cancer detection kitsthat aid in the early detection of bladder cancer, further reducing the disease burden.


COVID-19 Analysis of Bladder Cancer Detection Kit Market


The emergence of the pandemic has affected people across the globe and resulted in the shutdown of operational facilities worldwide. The healthcare industry is facingexceptional encounters during the lockdown phase. The manufacturing units were shut down,which also affected the production of medical products. The supply chain of the medical products was also affected, leading to the decrease in warehouse inventory of the manufactured products.


According to the mortality rates, bladder cancer cases surpass the COVID-19 cases worldwide and can be as high as 52% in 2020. Henceurologists are recommended not to postpone investigation.This resulted in increasing the demand for bladder cancer detection kits currently. This will further drive the growth of the bladder cancer detection kit market during the pandemic and is expected to grow rapidly during the post lockdown period.


Bladder Cancer Detection Kit Market Dynamics


Drivers



  • Increasing prevalence of bladder cancer

    • According to the World Cancer Research Fund (WCRF), bladder cancer is diagnosed in about 275,000 people each year, and approximately 108,000 people die due to bladder cancer globally. Moreover, bladder cancer is the sixth most commonly occurring cancer in men and the 17thmost commonly occurring cancer in women worldwide.

    • In 2018, the bladder cancer incidence rates per 100,000 population for men were highest in Greece at40.4%, followed by Lebanon at 40.0% and Denmark at 29.3% of men population. In females, Lebanon showed the highest incidence of 9.4 per 100,000 population. As the prevalence and mortality rate is rising worldwide, the demand for bladder cancer diagnosis is increasing. This further increases the investment in R&D of non-invasive bladder cancer detection products, hence driving the bladder cancer detection kit market growth.



  • Growing geriatric population

  • Rising investment in R&D activities for the production of bladder cancer detection kits


Bladder Cancer Detection Kit Market Restraints



  • Concerns pertaining to commercialization of the products in the developing countries


This product is based on new technology,with several products are in the R&D phase. The lack of awareness and demand for non-invasive bladder cancer detection kitshas limited the distribution of bladder cancer detection kits in emerging economies, especially in low- and lower-middle-income countries. The population base and prevalence of bladder cancer are higher in developing countries, but the traditional way of diagnosing it is still highly adopted due to its affordability. Hence, the commercialization of the approved products in these countries is less, which further hampers the growth of the bladder cancer detection kit market.


Technology Analysis

The bladder cancer detection kit is anon-invasive urine-based bladder cancer test kit developed in the last fewyears. The Abbott's (US) UroVysionbladder test kit is one of the US FDA-approved non-invasive test kits commonly used for bladder cancer detection in clinical settings.TheCxBladder Detectis a highly sensitive multi-gene urine biomarker test targeting MDK, CDC, IGF, HOXA, and IL8R. These test kits have higher sensitivity than urine cytology, but this technology is more complex and expensive. Since the advantages and sensitivity of these kits are much higher, the urologists recommend this non-invasive detection kit to reduce the use of invasive diagnostic procedures.


Bladder Cancer Detection Kit Market Segment Overview


By Technology



  • Fluorescence In Situ Hybridization (FISH):This technique is used in the field of urology to provide a non-invasive diagnostic application to replace cystoscopy. This is the special urine examination method used to detects genetic alterations of the urothelial cells found in the urine using fluorescent directlabeled DNA probes.UroVysion is one of the products based onthe FISH techniqueoffered by Abbott Laboratories (US).

  • Enzyme-Linked Immunosorbent Assay (ELISA):This technology is used to detect minichromosome maintenance complex component 5 (MCM5) protein, as MCM5 acts as a biomarker for cancer. This can also detect bladder cancer in people with symptoms associated with malignancy, including blood in the urine.

  • Others


By End User



  • Hospitals& Clinics:The advancement in the hospital infrastructure across the globe is driving the bladder cancer detection kit market. The investors are capitalizing on the bladder cancer domain by establishing hospitals for cancer diagnosis and treatment.

  • Diagnostic Centre:The demand for bladder cancer diagnosis is increasing, owing to the immediate diagnosisof the patient condition and no long queues. Such procedures are economicalat the diagnostic centers.

  • Others


Bladder Cancer Detection Kit Market Regional Analysis



  • North America


Rising prevalence of bladder cancer across the region is driving the North American bladder cancer detection kit market


North Americaholds the largest bladder cancer detection kit marketshare in 2020, owing to the rising prevalence of bladder cancer. According to the American Cancer Society, about 83,730 new cases of bladder cancer and approximately 17,200 deaths from bladder cancer occurred in the US in 2020. Moreover,well-established research organizations engaged in product development, the availability of innovative diagnostic products, and the presence of major players in the region further fuel the growth of the bladder cancer detection kit market. The prominent players are involved in expanding their operational facilities across the region, engaging in collaborations and partnerships, and launching new products for business growth.



  • Asia-Pacific


Rising prevalence of bladder cancer in aging populations fueling the Asia-Pacific bladder cancer detection kit market


Bladder cancer is primarily observed among older people aged between 65 to 85 years. In Japan, according to Globocan, it is estimated that about 37,000 new cases of bladder cancer are diagnosed per year and about 11,000 mortality per year from bladder cancer, andthe aging population is the main reason behind the surge of bladder cancer. In China, the aging population is expanding every year,and bladder cancer rates are increasing subsequently. It is estimated that the incidence rate of bladder cancer above age 65 is 49.6 per 100,000 people. Hence the rising rate of bladder cancer among elderly individuals and the increasing population of aging people in Asia-Pacific helps to drive the growth of the bladder cancer detection kit market.


Bladder Cancer Detection Kit Market- Competitive Landscape


The bladder cancer detection kit market is profitable, both for existing players as well as new entrants. Our analysis revealed that market players adopt different strategies and innovative R&D techniques to expand their business and secure their position in the bladder cancer detection kit market. Abbott Laboratories'(US)UroVysion bladder cancer kit (UroVysion Kit) was the first FDA-approved product distributed across the world.This product is designed to identify aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus through the FISH technology in urine specimens.Various other players also offer bladder cancer detection kits such as Cepheid's Xpert Bladder Cancer Detection, CxBladder Detect, a non-invasive, urine-based test thatoffers accurate results, is easier to use, and clinically validated in laboratory settings. Therefore, the industry players are coming up with various business strategies to increase their market presence. The companies invest in R&D activities to expand their product portfolio, further driving the bladder cancer detection kit market. In addition, the market players are adopting various strategies such as mergers &acquisitions, contractual agreements, new product launches, increasing investmentsin R&D, and partnering with other players to expand their global footprint.


List of Key Companies Covered in Bladder Cancer Detection Kit Market Report:



  • Abbott Laboratories (US)

  • Xiamen Biotime Biotechnology (China)

  • Exact Sciences (US)

  • Hubei Jinjian Biology (China)

  • Nanjing Liming Bio-products Co., Ltd (China)

  • Abingdon Health (UK)

  • Ameritek, Inc. (US)

  • Alfa Scientific Designs (US)

  • NanoEnTek Inc. (South Korea)

  • Diagnosis S.A. (Spain)

  • Xiamen Boson Biotech Co., Ltd (China)


Recent Developments



  • In May 2021, KDx Diagnostics (US) collaborated with Cardiff University, Cardiff and Vale University Health Board, or C&VUHB, and CellPathto develop its non-invasive bladder cancer test URO17.

  • In March 2021,a France-based OncoDiag company raised USD 3.0 million to commercialize its Urodiag PCR-based diagnostic test for recurrent bladder cancer in France.

  • In October 2015, Oxford Gene Technology (OGT) launched its CE-IVD labeled Cytocell Aquarius P16/3c/7c/17c Probe Kit for sale in Europe. It is a ready-to-use and cost-effective fluorescence in situ hybridization (FISH) probe kit used as a non-invasive detection of bladder cancer.


Report Overview


The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID on the bladder cancer detection kit market.


Bladder Cancer Detection Kit Market Scope of the Report & Segmentation


By Technology



  • Fluorescence In Situ Hybridization (FISH)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Others


By End User



  • Hospitals& Clinics

  • Diagnostic Centers

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027:~USD 322.4 Million
  CAGR   2027: ~11.17%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018-2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Technology and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain), Xiamen Boson Biotech Co., Ltd (China)
  Key Market Opportunities   The emergence of new products boost the market growth
  Key Market Drivers   Increasing prevalence of bladder cancer fuels market growth


Frequently Asked Questions (FAQ) :


The bladder cancer detection kit market is expected to cross ~USD 322.4 million by 2027.

Bladder Cancer Detection Kit Market is set to expand at a CAGR of 11.17% during the forecast period 2021 to 2027.

The growth of the Bladder Cancer Detection Kit Market is encouraged by the Increasing prevalence of bladder cancer, Growing geriatric population, Rising investment in R&D activities for the production of bladder cancer detection kits.

North America holds the largest bladder cancer detection kit marketshare in 2020, owing to the rising prevalence of bladder cancer. Rising prevalence of bladder cancer in aging populations fueling the Asia-Pacific bladder cancer detection kit market

The major players profiled by MRFR that are operating in the Bladder Cancer Detection Kit Market are Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain), Xiamen Boson Biotech Co., Ltd (China)

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting bladder cancer detection kittype

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY

6.1. Overview

6.2. Fluorescence In Situ Hybridization (FISH)

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Enzyme-Linked Immunosorbent Assay (ELISA)

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL BLADDER CANCER DETECTION KITMARKET, BY END USER

7.1. Overview

7.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Diagnostic Centers

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.4. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL BLADDER CANCER DETECTION KITMARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. US

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. Italy

8.3.4. Spain

8.3.5. UK

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Rest of the World

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Bladder Cancer Detection Kit Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of the Number of Developments in the Global Bladder Cancer Detection Kit Market

9.7. Key developments and Growth Strategies

9.7.1. New ProductLaunch/Service Deployment

9.7.2. Merger &Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2020

9.8.2. Major Players R&D Expenditure, 2020

10. COMPANY PROFILES

10.1. Abbott Laboratories

10.1.1. Company Overview

10.1.2. Product Offered

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Xiamen Biotime Biotechnology

10.2.1. Company Overview

10.2.2. Products Offered

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Exact Sciences

10.3.1. Company Overview

10.3.2. Products Offered

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Hubei Jinjian Biology

10.4.1. Company Overview

10.4.2. Products Offered

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Nanjing Liming Bio-products Co., Ltd

10.5.1. Company Overview

10.5.2. Products Offered

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Abingdon Health

10.6.1. Company Overview

10.6.2. Products Offered

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Ameritek, Inc.

10.7.1. Company Overview

10.7.2. Products Offered

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Alfa Scientific Designs

10.8.1. Company Overview

10.8.2. Products Offered

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. NanoEnTek Inc.

10.9.1. Company Overview

10.9.2. Products Offered

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Diagnosis S.A.

10.10.1. Company Overview

10.10.2. Products Offered

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Xiamen Boson Biotech Co., Ltd

10.11.1. Company Overview

10.11.2. Products Offered

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL BLADDER CANCER DETECTION KITMARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL BLADDER CANCER DETECTION KITMARKET ESTIMATES &FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 5 NORTH AMERICA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 6 NORTH AMERICA: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 7 US: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 8 US: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 9 CANADA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 10 CANADA: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 11 EUROPE: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 12 EUROPE: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 13 GERMANY: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 14 GERMANY: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 15 FRANCE: BLADDER CANCER DETECTION KIT MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 16 FRANCE: BLADDER CANCER DETECTION KIT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 17 ITALY: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 18 ITALY: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 19 SPAIN: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 20 SPAIN: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 21 UK: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 22 UK: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 23 REST OF EUROPE: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 24 REST OF EUROPE: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 25 ASIA-PACIFIC: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 27 JAPAN: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 28 JAPAN: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 29 CHINA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 30 CHINA: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 31 INDIA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 32 INDIA: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 33 AUSTRALIA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 34 AUSTRALIA: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

TABLE 35 SOUTH KOREA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 36 SOUTH KOREA: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

TABLE 37 REST OF ASIA-PACIFIC: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 38 REST OF ASIA-PACIFIC: BLADDER CANCER DETECTION KITMARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 39 REST OF THE WORLD: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 40 REST OF THE WORLD: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

TABLE 41 MIDDLE EAST: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 42 MIDDLE EAST: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

TABLE 43 AFRICA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 44 AFRICA: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

TABLE 45 LATIN AMERICA: BLADDER CANCER DETECTION KITMARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 46 LATIN AMERICA: BLADDER CANCER DETECTION KITMARKET, END USER, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BLADDER CANCER DETECTION KITMARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BLADDER CANCER DETECTION KITMARKET

FIGURE 4 GLOBAL BLADDER CANCER DETECTION KITMARKET SHARE, BY TECHNOLOGY, 2020 (%)

FIGURE 5 GLOBAL BLADDER CANCER DETECTION KITMARKET SHARE, BY END USER, 2020(%)

FIGURE 6 GLOBAL BLADDER CANCER DETECTION KITMARKET SHARE, BY REGION, 2020(%)

FIGURE 7 NORTH AMERICA: BLADDER CANCER DETECTION KITMARKET SHARE, BY REGION, 2020(%)

FIGURE 8 EUROPE: BLADDER CANCER DETECTION KITMARKET SHARE, BY REGION, 2020(%)

FIGURE 9 ASIA-PACIFIC: BLADDER CANCER DETECTION KITMARKET SHARE, BY REGION, 2020(%)

FIGURE 10 REST OF THE WORLD: BLADDER CANCER DETECTION KITMARKET SHARE, BY REGION, 2020(%)

FIGURE 11 GLOBAL BLADDER CANCER DETECTION KITMARKET: COMPANY SHARE ANALYSIS, 2020(%)

FIGURE 12 ABBOTT LABORATORIES: FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBOTT LABORATORIES: SWOT ANALYSIS

FIGURE 14 XIAMEN BIOTIME BIOTECHNOLOGY:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 15 XIAMEN BIOTIME BIOTECHNOLOGY:SWOT ANALYSIS

FIGURE 16 EXACT SCIENCES.:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 17 EXACT SCIENCES:SWOT ANALYSIS

FIGURE 18 EXACT SCIENCES:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 19 EXACT SCIENCES:SWOT ANALYSIS

FIGURE 20 HUBEI JINJIAN BIOLOGY:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 21 HUBEI JINJIAN BIOLOGY:SWOT ANALYSIS

FIGURE 22 NANJING LIMING BIO-PRODUCTS CO., LTD:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 23 NANJING LIMING BIO-PRODUCTS CO., LTD:SWOT ANALYSIS

FIGURE 24 ABINGDON HEALTH:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 25 ABINGDON HEALTH:SWOT ANALYSIS

FIGURE 26 AMERITEK, INC.: FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 27 AMERITEK, INC.: SWOT ANALYSIS

FIGURE 28 ALFA SCIENTIFIC DESIGNS: FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 29 ALFA SCIENTIFIC DESIGNS: SWOT ANALYSIS

FIGURE 30 NANOENTEK INC.:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 31 NANOENTEK INC.:SWOT ANALYSIS

FIGURE 32 DIAGNOSIS S.A.:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 33 DIAGNOSIS S.A.:SWOT ANALYSIS

FIGURE 34 XIAMEN BOSON BIOTECH CO., LTD:FINANANCIAL OVERVIEW SNAPSHOT

FIGURE 35 XIAMEN BOSON BIOTECH CO., LTD:SWOT ANALYSIS



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.